GB2276624B - Inactivation of cytotoxic drugs in the vascular compartment of a host - Google Patents

Inactivation of cytotoxic drugs in the vascular compartment of a host

Info

Publication number
GB2276624B
GB2276624B GB9410237A GB9410237A GB2276624B GB 2276624 B GB2276624 B GB 2276624B GB 9410237 A GB9410237 A GB 9410237A GB 9410237 A GB9410237 A GB 9410237A GB 2276624 B GB2276624 B GB 2276624B
Authority
GB
United Kingdom
Prior art keywords
inactivation
host
cytotoxic drugs
vascular compartment
vascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB9410237A
Other versions
GB2276624A (en
GB9410237D0 (en
Inventor
Kenneth Dawson Bagshawe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB9410237A priority Critical patent/GB2276624B/en
Publication of GB9410237D0 publication Critical patent/GB9410237D0/en
Publication of GB2276624A publication Critical patent/GB2276624A/en
Application granted granted Critical
Publication of GB2276624B publication Critical patent/GB2276624B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
GB9410237A 1992-01-09 1993-01-11 Inactivation of cytotoxic drugs in the vascular compartment of a host Expired - Fee Related GB2276624B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9410237A GB2276624B (en) 1992-01-09 1993-01-11 Inactivation of cytotoxic drugs in the vascular compartment of a host

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929200415A GB9200415D0 (en) 1992-01-09 1992-01-09 Inactivation of cytotoxic drugs
GB929204104A GB9204104D0 (en) 1992-01-09 1992-02-26 Inactivation of cytotoxic drugs
GB9410237A GB2276624B (en) 1992-01-09 1993-01-11 Inactivation of cytotoxic drugs in the vascular compartment of a host
PCT/GB1993/000040 WO1993013806A1 (en) 1992-01-09 1993-01-11 Inactivation of cytotoxic drugs

Publications (3)

Publication Number Publication Date
GB9410237D0 GB9410237D0 (en) 1994-07-27
GB2276624A GB2276624A (en) 1994-10-05
GB2276624B true GB2276624B (en) 1995-10-25

Family

ID=26300132

Family Applications (3)

Application Number Title Priority Date Filing Date
GB929200415A Pending GB9200415D0 (en) 1992-01-09 1992-01-09 Inactivation of cytotoxic drugs
GB929204104A Pending GB9204104D0 (en) 1992-01-09 1992-02-26 Inactivation of cytotoxic drugs
GB9410237A Expired - Fee Related GB2276624B (en) 1992-01-09 1993-01-11 Inactivation of cytotoxic drugs in the vascular compartment of a host

Family Applications Before (2)

Application Number Title Priority Date Filing Date
GB929200415A Pending GB9200415D0 (en) 1992-01-09 1992-01-09 Inactivation of cytotoxic drugs
GB929204104A Pending GB9204104D0 (en) 1992-01-09 1992-02-26 Inactivation of cytotoxic drugs

Country Status (5)

Country Link
EP (1) EP0620742A1 (en)
JP (1) JPH07506339A (en)
CA (1) CA2124217A1 (en)
GB (3) GB9200415D0 (en)
WO (1) WO1993013806A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264220A (en) * 1991-11-12 1993-11-23 Long David M Jr Method of extending the vascular dwell-time of particulate therapeutic and particulate diagnostic agents
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
GB9624993D0 (en) * 1996-11-30 1997-01-15 Aepact Ltd Tumour therapy
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
JP4554816B2 (en) * 1998-05-22 2010-09-29 アボット・ラボラトリーズ Anti-angiogenic drugs for the treatment of cancer, arthritis and retinopathy
CO5170498A1 (en) * 1999-05-28 2002-06-27 Abbott Lab BIARIL SULFONAMIDS ARE USEFUL AS CELL PROLIFERATION INHIBITORS
FR2883873B1 (en) 2005-03-31 2009-07-10 Pharmamens Sarl AGE INHIBITORS
US7732309B2 (en) * 2006-12-08 2010-06-08 Applied Materials, Inc. Plasma immersed ion implantation process
DK2603528T3 (en) * 2010-08-10 2016-11-28 Glycotope Gmbh FAB-glycosylated ANTIBODIES
CN117815404A (en) 2018-05-18 2024-04-05 第一三共株式会社 anti-MUC 1 antibody-drug conjugates

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007378A1 (en) * 1987-03-09 1988-10-06 Cancer Research Campaign Technology Ltd. Improvements relating to drug delivery systems
EP0308208A1 (en) * 1987-09-14 1989-03-22 Center For Molecular Medicine And Immunology Modified antibody conjugates with enhanced clearance
WO1989010140A1 (en) * 1988-04-22 1989-11-02 Cancer Research Campaign Technology Limited Further improvements relating to drug delivery systems
WO1990009134A1 (en) * 1989-02-13 1990-08-23 Cosgrove James H Device for releasably supporting a plurality of objects
WO1990010460A1 (en) * 1989-03-13 1990-09-20 Kenneth Naoyuki Matsumura Method for reducing side effects of a drug
EP0506124A1 (en) * 1991-03-27 1992-09-30 Tanox Biosystems, Inc. Methods and substances for recruiting therapeutic agents to solid issues comprising two single chain VH-VL bifunctional binding molecules

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009134A1 (en) * 1989-12-15 1991-06-27 Takeda Chemical Industries, Ltd. Biospecific antibody to cancer cell and enzyme with prodrug-activating characteristics

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007378A1 (en) * 1987-03-09 1988-10-06 Cancer Research Campaign Technology Ltd. Improvements relating to drug delivery systems
EP0308208A1 (en) * 1987-09-14 1989-03-22 Center For Molecular Medicine And Immunology Modified antibody conjugates with enhanced clearance
WO1989010140A1 (en) * 1988-04-22 1989-11-02 Cancer Research Campaign Technology Limited Further improvements relating to drug delivery systems
WO1990009134A1 (en) * 1989-02-13 1990-08-23 Cosgrove James H Device for releasably supporting a plurality of objects
WO1990010460A1 (en) * 1989-03-13 1990-09-20 Kenneth Naoyuki Matsumura Method for reducing side effects of a drug
EP0506124A1 (en) * 1991-03-27 1992-09-30 Tanox Biosystems, Inc. Methods and substances for recruiting therapeutic agents to solid issues comprising two single chain VH-VL bifunctional binding molecules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Antibody,Immunoconjugates,Radiopharm. 1988,1(2),169-180 *
Proc.Natl.Acad.Sci.USA 1983,80,3078-3080 *

Also Published As

Publication number Publication date
JPH07506339A (en) 1995-07-13
WO1993013806A1 (en) 1993-07-22
GB2276624A (en) 1994-10-05
GB9410237D0 (en) 1994-07-27
GB9204104D0 (en) 1992-04-08
GB9200415D0 (en) 1992-02-26
CA2124217A1 (en) 1993-07-22
EP0620742A1 (en) 1994-10-26

Similar Documents

Publication Publication Date Title
GB9410236D0 (en) Cytotoxic drug therapy
GB8820945D0 (en) Medical articles
IL107411A0 (en) Infusion administering catheter holder
GB8906756D0 (en) Medication container
EP0351687A3 (en) Vascular catheter
AU4854393A (en) Self-introducing infusion catheter
AU4227793A (en) Drug infuser
AU7673694A (en) Simultaneous angioplasty and drug delivery
HK1000279A1 (en) Medical bag
IL91181A0 (en) Cytotoxic drug conjugates
PH27351A (en) Cytotoxic drug conjugates
ZA939317B (en) Medicament
GB2276624B (en) Inactivation of cytotoxic drugs in the vascular compartment of a host
NZ257470A (en) 5-hydrazino-quinolone derivatives and antimicrobial medicaments
AU7472994A (en) Polyesters for use in blood partitioning
HUT57669A (en) Auotmatic shelf container
GB9119793D0 (en) Medicine containers
NZ248041A (en) Aminoalkyl- tetrahydrofuran derivatives and medicaments
AU667546C (en) Medicine container
GB9000627D0 (en) Medicament container
GB9013977D0 (en) Medicament container
GB8814739D0 (en) Medicament container
GB8821699D0 (en) Medicament container
GB8821698D0 (en) Medicament container
GB8814740D0 (en) Medicament container

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20010111